:
Diabetic cardiomyopathy (DCM) is a significant complication of diabetes mellitus characterized by gradual
failing heart with detrimental cardiac remodellings such as fibrosis and diastolic and systolic dysfunction, which is not
directly attributable to coronary artery disease. Insulin resistance and resulting hyperglycemia is the main trigger involved in
the initiation of diabetic cardiomyopathy. There is a constellation of many pathophysiological events such as lipotoxicity,
oxidative stress, inflammation, inappropriate activation of the renin-angiotensin-aldosterone system, dysfunctional immune
modulation promoting increased rate of cardiac cell injury, apoptosis, and necrosis which ultimately culminates into
interstitial fibrosis, cardiac stiffness, diastolic dysfunction initially and later systolic dysfunction too. These events finally
lead to clinical heart failure of DCM. Herein, we have briefly discussed the pathophysiology of DCM. We have also briefly
mentioned potential therapeutic strategies currently used for DCM.
